Abeona Therapeutics announces first patient treatment with ZEVASKYN

Abeona Therapeutics (ABEO) announced the first commercial patient treatment with FDA-approved ZEVASKYN, a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Children’s Hospital Stanford in Palo Alto, CA. “Treating our first patient is a proud moment for Abeona and a testament to the tireless resolve of our team,” said Vish Seshadri, Chief Executive Officer of Abeona. “We are humbled to bring ZEVASKYN to the RDEB community and grateful to our growing network of Qualified Treatment Centers. Momentum is building, with additional patients already scheduled for treatment in the new year.”